Hundreds of industry experts gathered in Rongcheng to create a new ecosystem of pharmaceutical industry

In the past decade, remarkable achievements have been made in the field of tumor immunity, especially after major breakthroughs have been made in the new treatment schemes such as PD-1 / PD-L1 monoclonal antibody, cell therapy, oncolytic virus, etc., which are used for up to 10 kinds of tumor treatment, tumor immunotherapy drugs have increasingly become the research focus of research institutions and pharmaceutical enterprises However, with the rapid development of tumor immunotherapy, its unique characteristics bring new difficulties and challenges to the design and evaluation of clinical trials Therefore, how can the industry break through the technical problems of tumor immunotherapy research and development? How can the innovation elements of local biomedical industry accurately implement the deep integration of professional chain, industrial chain and innovation chain? How can enterprises utilize the resources of domestic research institutions to achieve innovation empowerment? 　　 On December 7-8, the 2019biotianfu tumor immunity Industry University Research Integration Innovation Summit Forum and the 20th interferon and cytokine academic annual meeting were held in Chengdu high tech Zone The meeting was hosted by the interferon and cytokine Professional Committee of China Society of Microbiology, Jiangsu Biotechnology Association, Chengdu high investment Biomedical Park Management Co., Ltd (Tianfu Life Science Park), and the meeting Jointly organized by the Chinese medicine and coffee industry The conference gathered Hou Yunde, academician of Chinese Academy of engineering, Wei Yuquan, academician of Chinese Academy of Sciences, more than 10 international top academic experts, more than 50 professors of scientific research institutes, and more than 200 senior executives of famous domestic pharmaceutical companies and other distinguished guests to exchange and collide on the latest development and future trend of interferon and cytokine related molecules At the same time, the conference also held the innovation forum for scientific and technological talents in Colleges and universities, the conference for transfer and transformation of scientific research achievements and matching talents, and helped the leapfrog development of interferon, cytokine related molecules, tumor immune regulatory molecules and other fields in China from all aspects and in many ways Focusing on the cutting-edge perspective in the field of tumor immunity, academician Hou Yunde, academician Wei Yuquan, Professor Gen Sheng Feng, Professor Fu Xinyuan The rapid development of basic research and science and technology in the field of tumor immunology provides a deep knowledge deposit and technical reserve for the development of tumor immunodrugs, and promotes the explosive growth of tumor immunodrugs Hou Yunde, academician of Chinese Academy of engineering, expert of Medical Virology, director of Laboratory of Institute of viral disease prevention and control of China Center for Disease Control and prevention, winner of 2017 national highest science and technology award, academician of Chinese Academy of Sciences, professor and doctoral supervisor of Sichuan University, Professor Feng Gensheng, pathology and molecular biology of University of California, San Diego, USA International well-known molecular biomedical and biochemical scholars, and Professor Fu Xinyuan of Chengdu West China Hospital respectively brought their own research findings in related fields, which attracted the attention and hot discussion of the guests present Mr Gu xingchu, Mr Rao Chunming, Mr Han aiming, in recent years, the State Food and Drug Administration and other departments have strengthened supervision, and innovative drugs have gone through structural design, discovery, pre clinical research, clinical research and finally approved for listing, with a long time and complicated process For most pharmaceutical enterprises, how to improve the pass rate of new drug application and speed up the new drug to enter the clinical research stage is still an urgent problem At this meeting, Dr Gu xingchu, vice president of preclinical research department of Shanghai meidixi biomedical Co., Ltd., elaborated on the characteristics, pharmacodynamics, pharmacokinetics, safety research strategies of protein / antibody drugs, and provided suggestions for the pain of new drug research and development In addition, on the in-depth discussion of biotechnological drugs, Rao Chunming, director of the recombinant Drug Department of the Institute of biological control of the Chinese Academy of inspection, introduced the research basis and relevant progress of biotechnological drug quality standards in China, focusing on the technical hard core content such as the quality control standards and analysis methods of recombinant drugs On the other hand, Han aiming, general manager of Greater China region of pronorson Biotechnology (Shanghai) Co., Ltd., has put forward innovative solutions for macromolecular Biopharmaceutics with a market of 100 billion yuan due to its natural "defects" such as large molecular weight and complex modification Mr Cen Xiaobo and Mr Tao Weikang are sharing the cutting-edge perspective and discussing the key R & D technologies Besides, their discussion on immune checkpoints in tumor immunity is also a highlight CEN Xiaobo, CEO and center director of Chengdu Huaxi Haiqi Pharmaceutical Technology Co., Ltd., shared the important considerations of non clinical evaluation of immunosuppressive checkpoint inhibitors, which provided a new idea for tumor immunotherapy Deputy general manager and CEO of R & D center of Jiangsu Hengrui Pharmaceutical Co., Ltd introduced the current situation and challenges of cytokines in tumor immunotherapy, and discussed the role of cytokines in tumor immunotherapy Mr Cui Daxiang, Mr Xing Tongjing, as the middle force of domestic drug research and development, scientific research institutes and universities have also brought issues related to tumor immunity or interferon Cui Daxiang, vice president of the Institute of Nanobiomedical engineering and the Institute of translational medicine of Shanghai Jiaotong University, shared a report entitled "Research on nanoparticle labeled immunocell targeted imaging and synergistic treatment of tumor" And director Xing Tongjing, liver disease center of infection department, Taizhou hospital, Zhejiang Province, delivered a wonderful speech entitled "research progress of interferon application in the functional cure of chronic hepatitis B" Mr Zhu Huaxing, Mr Chen Ping, Mr Zhang Qinghua, Mr Yang Zhihua, Mr Xing Tongjing, Mr Cui Daxiang, Mr Han aiming, Mr Rao Chunming In recent years, the breakthrough of adoptive cellular immunotherapy and immunocheckpoint therapy represented by car-t in the field of tumor therapy has attracted wide attention in the industry The technological evolution is accelerating the penetration of cell therapy mainly based on stem cells and tumor immune cells in the global scope Since the U.S FDA approved two car-t therapies (kymriah and yescarta) to be launched in 2017, a new round of industrialization of cell-based therapy has come to the world At present, China's prospects in the field of cells are second only to the United States, becoming the second largest market in the world However, in this "overheated" situation, the scientific research community, the pharmaceutical industry, the business community and the investment community hold different attitudes towards the industrialization of cell therapy For example, car-t therapy has encountered difficulties in the effectiveness, safety and policy supervision of solid tumor treatment, that is, cell therapy has to go from clinical to industrialization, with great challenges 　　 Next, Mr Zhu Huaxing, CEO of inshore protein Technology Co., Ltd., Mr Chen Ping, President of CBA, Mr Zhang Qinghua, founder of Shanghai Huaying Biomedical Technology Co., Ltd., Mr Yang Zhihua, director of drug safety / vigilance of Fang en medicine, Mr Xing Tongjing, director of Hepatology center of infection department, Taizhou hospital, Zhejiang Province, and transformation of Shanghai Jiaotong University Mr Cui Daxiang, vice president of the Institute of nano biomedical engineering, Mr Han aiming, general manager of Greater China of proeinsimple Biotechnology Co., Ltd., and Mr Rao Chunming, director of the recombination Medicine Department of the Institute of biological control of the Chinese Academy of Medical Sciences, discussed and shared the evaluation of cytokine industry under the development of precision therapy Help to build an industrial ecosystem and form an industrial cluster in Tianfu life science and Technology Park Biopharmaceutical industry has become a new engine of global economic development Based on the research on the development advantages and successful experience of key biopharmaceutical clusters in the world, a large number of domestic biopharmaceutical industrial parks have emerged They actively embrace the innovation era, form industry clusters for scientific research and innovation, and promote integrated development During the conference, the Biological Industry Development Bureau of Chengdu high tech Zone made a recommendation on the biological industry of Chengdu high tech Zone, and the industrial advantages of Chengdu high tech Zone and Tianfu Life Science Park were concerned As the main position of Chengdu biomedical industry, Chengdu high tech Zone is aiming to build a modern biological industry system with international competitiveness and regional driving force, and accelerate the building of "four chains, one community, one system" industrial ecosystem Since this year, Chengdu hi tech Zone has successively introduced a number of projects, such as Gilead science West operation center, Elgin China pharmaceutical trade headquarters, Boston Science China second headquarters and innovation center, and aikunwei West operation headquarters Chengdu high tech Zone continued to promote the cultivation of innovative varieties, promoted 3 class 1 biological products to obtain clinical licenses, 27 class 1 new drugs to enter the clinical stage, and 9 drugs and 20 medical device varieties to obtain production approval and registration certificates In 2019, the main business income of the pharmaceutical industry in Chengdu high tech Zone is expected to reach 24.3 billion yuan, an increase of 18% year-on-year, and the scale of the biological industry will exceed 50 billion yuan for the first time 　　 As the oldest biomedical industrial park in Chengdu high tech Zone, Tianfu life science and technology park is a biomedical R & D innovation center and industrial incubation center built in Chengdu, Sichuan Province At present, it has gathered more than 6000 biomedical practitioners, introduced domestic and foreign well-known enterprises represented by Huaxi Hospital, Hengrui medicine, intelligent chemistry and good doctor medicine, and Kangnuo There are 174 innovative and entrepreneurial enterprises represented by Asia, xilingyuan, antjin and McConnell More than 400 international and domestic first-class projects have been gathered, including more than 50 new drug projects under research "After 10 years of operation and development, Tianfu life science and technology park has gathered many innovative bio pharmaceutical enterprises in the park Through enterprise interaction, it has formed industrial agglomeration, laying a foundation for the development of Bio Industry in Chengdu high tech Zone." Chengdu high tech Zone Tianfu Life Science Park said As a cooperation project between Sichuan University and Chengdu high tech Zone, part of carriers of Tianfu Life Science Park Phase II cooperate with Sichuan University to build Chengdu Frontier Medical Center The center aims to build an international first-class "medical +" innovation research, project incubation and industry introduction highland The first carriers have been delivered in September this year Meeting highlights